759 related articles for article (PubMed ID: 23034825)
1. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
2. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
[TBL] [Abstract][Full Text] [Related]
4. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
5. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
7. Recombinant peptides in thrombolysis.
Campbell J; Hilleman D
Semin Thromb Hemost; 2010 Jul; 36(5):529-36. PubMed ID: 20632250
[TBL] [Abstract][Full Text] [Related]
8. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
Bell WR
Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on reteplase in thrombotic occlusive disorders.
Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
[TBL] [Abstract][Full Text] [Related]
10. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
11. [Local thrombolysis in peripheral arterial occlusion].
Hess H
Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076
[TBL] [Abstract][Full Text] [Related]
12. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
[TBL] [Abstract][Full Text] [Related]
14. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.
Kawata H; Uesugi Y; Soeda T; Takemoto Y; Sung JH; Umaki K; Kato K; Ogiwara K; Nogami K; Ishigami K; Horii M; Uemura S; Shima M; Tabata Y; Saito Y
J Am Coll Cardiol; 2012 Dec; 60(24):2550-7. PubMed ID: 23158532
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown.
Gurewich V
Cardiovasc Drugs Ther; 2019 Dec; 33(6):749-753. PubMed ID: 31897763
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.
Zamanlu M; Farhoudi M; Eskandani M; Mahmoudi J; Barar J; Rafi M; Omidi Y
J Drug Target; 2018 Feb; 26(2):95-109. PubMed ID: 28796540
[TBL] [Abstract][Full Text] [Related]
17. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
18. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
Ma H; Jiang Z; Xu J; Liu J; Guo ZN
Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
[TBL] [Abstract][Full Text] [Related]
19. Serine-proteases as plasminogen activators in terms of fibrinolysis.
Flemmig M; Melzig MF
J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
[TBL] [Abstract][Full Text] [Related]
20. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
